Business
Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
Randomized phase of XanaMIA pivotal trial of oral Xanamem 10 mg remains on track for topline final results in November 2026SYDNEY, April 01, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the first participant has been treated in the open-label extension (OLE) phase of the XanaMIA trial following completion of 36 weeks of treatment in the randomized phase. Highlights of the OLE: Open-label phase of up to 25 months duration, during which all participants will receive
About this update from Actinogen Medical Limited
[{"type":"image","alt":"Actinogen Medical","displaySize":"","headline":null,"caption":"Actinogen Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/3b4990d3680eb8b749faad86ae930ad4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AWOCuFgwp1BOYBkQLGHPnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/3b4990d3680eb8b749faad86ae930ad4","width":300,"height":300}},"lazy":false},{"type":"text","content":"Randomized phase of XanaMIA pivotal trial of oral Xanamem 10 mg remains on track for topline final results in November 2026","length":123,"tagName":"p"},{"type":"text","content":"SYDNEY, April 01, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the first participant has been treated in the open-label extension (OLE) phase of the XanaMIA trial following completion of 36 weeks of treatment in the randomized phase.","length":270,"tagName":"p"},{"type":"text","content":"Highlights of the OLE:","length":22,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Open-label phase of up to 25 months duration, during which all participants will receive active Xanamem® 10 mg once daily, with no placebo control group","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Open to all former and current participants who have completed the randomized phase of the XanaMIA pivotal Alzheimer’s disease trial in Australia and the United States","length":167,"tagName":"p"}]},{"val":[{"type":"text","content":"Generates longer term safety data and observational data on key efficacy endpoints including CDR- SB1, cognition and activities of daily living","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"Data will be analyzed and reported progressively and compared with relevant historical control cohorts of patients with mild to moderate Alzheimer’s disease, as well as with data from the randomized phase of the trial.","length":218,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":685,"olType":false},{"type":"text","content":"Dr Dana Hilt, the Company’s CMO said:","length":37,"tagName":"p"},{"type":"text","content":"“The commencement of the open-label extension phase of the XanaMIA trial enables us to offer current and past participants access to active ...